Disease
Chronic Kidney Disease
Progressive loss of kidney function (reduced eGFR and/or albuminuria) over 3+ months, spanning stages 1-5 up to but not including dialysis-dependent end-stage renal disease.
Total attributable cost
$646.5B
$17,472/patient
Drug spend
$50.3B
$1,359/patient
8% of total cost is drugs
All stages, non-dialysis (national surveillance estimate, updated 2026-03) · US